Prognostic Factors for Renal Cell Carcinoma With Bone Metastasis: Who Are the Long-Term Survivors?-Reference-Cited by-同舟云学术

Prognostic Factors for Renal Cell Carcinoma With Bone Metastasis: Who Are the Long-Term Survivors?

Published:2011-05 Issue:5 Volume:185 Page:1611-1614
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Kume Haruki¹,Kakutani Shigenori²,Yamada Yukio³,Shinohara Mitsuru³,Tominaga Takashi²,Suzuki Motofumi¹,Fujimura Tetsuya¹,Fukuhara Hiroshi¹,Enomoto Yutaka¹,Nishimatsu Hiroaki¹,Homma Yukio¹

Affiliation:

1. Department of Urology, University of Tokyo Hospital, Tokyo, Japan

2. Department of Urology, Mitsui Memorial Hospital, Tokyo, Japan

3. Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference14 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma;Henriksson;Scand J Urol Nephrol,1992

3. Local progression after operative treatment of metastatic kidney cancer;Les;Clin Orthop Relat Res,2001

4. Patient survival after surgery for osseous metastases from renal cell carcinoma;Lin;J Bone Joint Surg Am,2007

5. Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma;Althausen;Cancer,1997

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Bone metastasis risk and prognosis assessment models for kidney cancer based on machine learning;Frontiers in Public Health;2022-11-17

3. The histopathology of skeletal metastases;Bone Cancer;2022

4. Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries;Frontiers in Oncology;2021-09-17

5. A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab;Targeted Oncology;2021-08-11